Skip to main content

Lexapro Disease Interactions

There are 9 disease interactions with Lexapro (escitalopram).

Major

SSRI antidepressants (applies to Lexapro) depression

Major Potential Hazard, Moderate plausibility. Applicable conditions: Psychosis

Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior. Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes. Families and caregivers should be advised of the need for close observation and communication with the treating physician. Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset. It may be prudent to refrain from dispensing large quantities of medication to these patients.

References

  1. "Product Information. Zoloft (sertraline)." Roerig Division (2001):
  2. "Product Information. Prozac (fluoxetine)." Dista Products Company (2001):
  3. "Product Information. Paxil (paroxetine)." GlaxoSmithKline (2001):
  4. "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc (2001):
  5. "Product Information. Celexa (citalopram)." Forest Pharmaceuticals (2001):
  6. "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals (2002):
View all 6 references
Moderate

Citalopram (applies to Lexapro) renal dysfunction

Moderate Potential Hazard, Low plausibility.

Citalopram (racemic) and escitalopram (the more pharmacologically active S-enantiomer) are extensively metabolized and only small amounts are excreted unchanged in the urine. No dosage adjustments are necessary in patients with mild to moderate renal impairment, as the oral clearance of citalopram has been shown to decrease only modestly (17%) in these patients compared to those with normal renal function. There is no information on the pharmacokinetics of citalopram or escitalopram in patients with severe renal impairment (CrCl < 20 mL/min). Therapy with these agents should be administered cautiously in such patients.

References

  1. "Product Information. Celexa (citalopram)." Forest Pharmaceuticals (2001):
  2. "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals (2002):
Moderate

SSRI (applies to Lexapro) hyponatremia

Moderate Potential Hazard, Moderate plausibility.

Treatment with SSRI antidepressants can cause hyponatremia. Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.

References

  1. "Product Information. Zoloft (sertraline)." Roerig Division (2001):
  2. "Product Information. Prozac (fluoxetine)." Dista Products Company (2001):
  3. "Product Information. Paxil (paroxetine)." GlaxoSmithKline (2001):
  4. "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc (2001):
  5. "Product Information. Celexa (citalopram)." Forest Pharmaceuticals (2001):
  6. "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals (2002):
View all 6 references
Moderate

SSRIs (applies to Lexapro) liver disease

Moderate Potential Hazard, High plausibility.

Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver. The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function. Dosage adjustments may be necessary in accordance with the individual product package labeling.

References

  1. Wolen RL, Lemberger L, Bergstrom RF, Schenker S "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988): 353-9
  2. Caillard V, Doogan DP "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988): 46-51
  3. Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991): 952-61
  4. McTavish D, Murdoch D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992): 604-24
  5. "Product Information. Zoloft (sertraline)." Roerig Division (2001):
  6. "Product Information. Prozac (fluoxetine)." Dista Products Company (2001):
  7. Gram LF, Lund J, Mengel H, Pedersen OL, Kristensen CB, Thayssen P "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982): 351-7
  8. Vlahov V, Maleev A, Terziivanov D, Wolf D, Dierdorf HD, Eckl KM, Greb WH, Krastev Z "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989): 91-2
  9. Langley PF, Haddock RE, Kaye CM, Mellows G, Greb WH, Tasker TC, Zussman BD "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989): 60-75
  10. "Product Information. Paxil (paroxetine)." GlaxoSmithKline (2001):
  11. Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986): 313-34
  12. Benfield P, Wilde MI, Plosker GL "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993): 895-924
  13. "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc (2001):
  14. Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994): 1359-69
  15. van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993): 203-20
  16. "Product Information. Celexa (citalopram)." Forest Pharmaceuticals (2001):
  17. "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals (2002):
View all 17 references
Moderate

SSRIs (applies to Lexapro) mania

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Bipolar Disorder, Depression

Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania. The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs. Patients with bipolar disorder are generally more likely to experience mania from antidepressants. Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder. Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.

References

  1. Bernardo M, Vieta E "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992): 1282-3
  2. Korsak C, Bartos M, Quant R, Beal DM, Harris D, Splane G, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991): 1751
  3. Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991): 1404
  4. Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990): 1569
  5. Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992): 107
  6. Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991): 952-61
  7. McTavish D, Murdoch D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992): 604-24
  8. Chouinard G, Beauclair L, Goldbloom D, Laporta M "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987): 1513-4
  9. Bellodi L, Mundo E, Ronchi P "Drug-induced mania." Hosp Community Psychiatry 44 (1993): 689-90
  10. "Product Information. Zoloft (sertraline)." Roerig Division (2001):
  11. "Product Information. Prozac (fluoxetine)." Dista Products Company (2001):
  12. Blumhardt CL, Boyer WF "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992): 61-6
  13. "Product Information. Paxil (paroxetine)." GlaxoSmithKline (2001):
  14. Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993): 698-9
  15. Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993): 603-30
  16. Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994): 549-50
  17. Bocchetta A, Burrai C, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991): 1263-4
  18. Aronzon R, Frankel Y, Bar-Halperin A, Dorevitch A, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993): 1455-7
  19. Pearce GL, Edwards JG, Inman WH, Wilton L "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994): 387-95
  20. Vlaskamp H, Wagner W, Essers H, Gray TE, Plekkenpol B "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992): 48-53;disc. 53-4
  21. Greist JH, Perse TL, Jefferson JW, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991): 391-2
  22. Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994): 78-9
  23. "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc (2001):
  24. Abbate L, Liebowitz MR, Cardenas D, Printz D, Marshall RD "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995): 1238-9
  25. Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996): 425-7
  26. "Product Information. Celexa (citalopram)." Forest Pharmaceuticals (2001):
  27. "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals (2002):
View all 27 references
Moderate

SSRIs (applies to Lexapro) platelet function

Moderate Potential Hazard, High plausibility. Applicable conditions: Bleeding, Coagulation Defect, Thrombocytopathy, Thrombocytopenia, Vitamin K Deficiency

The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function. Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported. Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.

References

  1. Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992): 412
  2. Kirschen H, Mosberg HJ, Ninan P, Yaryura-Tobias JA "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991): 949
  3. VandenBerg SR, Humphries JE, Wheby MS "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990): 727-8
  4. Alderman CP, Ben-Tovim DI, Moritz CK "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9
  5. "Product Information. Zoloft (sertraline)." Roerig Division (2001):
  6. "Product Information. Prozac (fluoxetine)." Dista Products Company (2001):
  7. "Product Information. Paxil (paroxetine)." GlaxoSmithKline (2001):
  8. Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993): 603-30
  9. Stricker BH, Huls J, Ottervanger JP, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994): 781-2
  10. "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc (2001):
  11. Wiener J, Krivy J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995): 132
  12. Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996): 12-6
  13. Kelly MW, Pai VB "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996): 786-8
  14. Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996): 1232-4
  15. Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996): 604-5
  16. "Product Information. Celexa (citalopram)." Forest Pharmaceuticals (2001):
  17. Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998): 25-30
  18. Aigner M, Drucker C, Eichler HG, Entlicher J, Hergovich N, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000): 435-42
View all 18 references
Moderate

SSRIs (applies to Lexapro) seizure disorders

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Seizures

Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy. Therapy with SSRIs should be administered cautiously in patients with seizure disorders.

References

  1. Hargrave R, Bernstein AJ, Martinez D "Fluoxetine-induced seizures." Psychosomatics 33 (1992): 236-9
  2. Caillard V, Doogan DP "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988): 46-51
  3. Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991): 952-61
  4. McTavish D, Murdoch D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992): 604-24
  5. "Product Information. Zoloft (sertraline)." Roerig Division (2001):
  6. "Product Information. Prozac (fluoxetine)." Dista Products Company (2001):
  7. Blumhardt CL, Boyer WF "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992): 61-6
  8. "Product Information. Paxil (paroxetine)." GlaxoSmithKline (2001):
  9. Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993): 603-30
  10. Hoffman JS, Kenin M, Levine R, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994): 145-6
  11. Madi L, Fennell J, Obrien AAJ "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994): 383-4
  12. Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994): 127-38
  13. Wait CM, Spivey KM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993): 321
  14. Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991): 433-5
  15. Pearce GL, Edwards JG, Inman WH, Wilton L "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994): 387-95
  16. Vlaskamp H, Wagner W, Essers H, Gray TE, Plekkenpol B "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992): 48-53;disc. 53-4
  17. "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc (2001):
  18. Abbate L, Liebowitz MR, Cardenas D, Printz D, Marshall RD "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995): 1238-9
  19. "Product Information. Celexa (citalopram)." Forest Pharmaceuticals (2001):
  20. Hawley JM, Kim KY, Craig JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000): 1276-8
  21. "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals (2002):
View all 21 references
Moderate

SSRIs (applies to Lexapro) SIADH

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Dehydration, Hyponatremia

The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH). These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention. SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy. Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH. Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.

References

  1. Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983): 708-10
  2. Cusano W, Navalgund AA, Vishwanath BM, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991): 542-3
  3. Clayton AH, Staab JP, Yerkes SA, Cheney EM "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990): 1569-70
  4. Adler L, Mahelsky M, Cohen BJ "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990): 948-9
  5. Miller LG, Noel ML, Jr Hall DL, Kazal LA "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993): 341-3
  6. Crews JR, Lipper S, Schreiber J, Potts NL "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993): 1564
  7. Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993): 723-4
  8. "Product Information. Zoloft (sertraline)." Roerig Division (2001):
  9. "Product Information. Prozac (fluoxetine)." Dista Products Company (2001):
  10. Vong SK, Chua TP "Hyponatraemia associated with paroxetine." BMJ 306 (1993): 143
  11. Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992): 1332
  12. "Product Information. Paxil (paroxetine)." GlaxoSmithKline (2001):
  13. Borison R, Doshi D "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994): 779-80
  14. Coulter DM, Pillans PI "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994): 85-6
  15. Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993): 62-3
  16. "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc (2001):
  17. Gorelick M, Llorente MD, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994): 543-4
  18. Resch DS, Thornton SL "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995): 809
  19. Carson W, Jackson C, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995): 809-10
  20. Ayonrinde OT, Sanfilippo FM, Reutens SG "Paroxetine-induced SIADH." Med J Aust 163 (1995): 390
  21. Samuels SC, Kessler J "Sertraline and hyponatremia." N Engl J Med 335 (1996): 524
  22. Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996): 680-3
  23. "Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996): 562
  24. Robinson D, Brooks J, Sheikh JI, Mahler E "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996): 885
  25. Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996): 1413
  26. Smythe MA, Woo MH "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997): 108-10
  27. Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997): 580
  28. Bonmarchand G, Goulle JP, Chevron V, Droy JM, Girault C, Leroy J, Richard JC "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997): 93-5
  29. Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997): 306-7
  30. Knowles SR, Mittmann N, Shear NH, Liu BA "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996): 519-27
  31. "Product Information. Celexa (citalopram)." Forest Pharmaceuticals (2001):
  32. Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998): 25-30
  33. "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals (2002):
  34. Gates JR, Palmer BF, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003): 1694-702
  35. Twardowschy CA, Bertolucci CB, Brandao MA, Gracia Cde M "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006): 142-5
View all 35 references
Minor

SSRIs (applies to Lexapro) weight loss

Minor Potential Hazard, Moderate plausibility. Applicable conditions: Anorexia/Feeding Problems, Malnourished, Weight Loss/Failure to Thrive

The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss. Anorexia may occur in approximately 5% to 10% of patients. Weight change should be monitored during therapy if an SSRI is used in these patients.

References

  1. Baca E, Caballero L, Iruela LM, Oliveros SC "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992): 1113-4
  2. "Product Information. Zoloft (sertraline)." Roerig Division (2001):
  3. "Product Information. Prozac (fluoxetine)." Dista Products Company (2001):
  4. "Product Information. Paxil (paroxetine)." GlaxoSmithKline (2001):
  5. Salcedo MS, Vaz FJ "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994): 118-9
  6. Jaramillo JDC, Meyerowitz W "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994): 1176-81
  7. Fernstrom MH, Kupfer DJ, Massoudi M "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988): 948-9
  8. Vlaskamp H, Wagner W, Essers H, Gray TE, Plekkenpol B "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992): 48-53;disc. 53-4
  9. "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc (2001):
  10. Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994): 1350-2
  11. "Product Information. Celexa (citalopram)." Forest Pharmaceuticals (2001):
View all 11 references

Lexapro drug interactions

There are 666 drug interactions with Lexapro (escitalopram).

Lexapro alcohol/food interactions

There is 1 alcohol/food interaction with Lexapro (escitalopram).

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.